Discovery and Development of NVB302, a Semisynthetic Antibiotic for Treatment of Clostridium difficile Infection

Natural Products: Discourse, Diversity, and Design

Volumn , Issue , 2014, Pages 455-468

  Boakes, Steven ^a   Dawson, Michael J ^a  

^a Novacta Biosystems Ltd   (United Kingdom)

Author keywords

C.difficile infection; Lantibiotic biosynthesis; NVB302; Semisynthetic antibiotic

Indexed keywords

EID: 84926435429     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118794623.ch24     Document Type: Chapter

References (22)

1. Widdick, D.A.; Dodd, H.M.; Barraille, P.; White, J.; Stein, T.H.; Chater, K.F.; Gasson, M.J.; Bibb, M.J., Cloning and engineering of the cinnamycin biosynthetic gene cluster from Streptomyces cinnamoneus cinnamoneus DSM4005. Proc. Natl. Acad. Sci. USA 2003, 100 (7), 4316-4321.
2. Coronelli, C.; Tamani, G.; Lancini, G.C. Gardimycin, a new antibiotic from Actinoplanes. II. Isolation and preliminary characterisation. J. Antibiot. 1976, 29 (5), 507-510.
3. Chatterjee, S.; Chatterjee, D.K.; Joni, R.H.; Blumbach, J.; Ganguli, B.N.; Klesel, N.; Limbert, M.; Seibert, G. Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiot. 1992, 45 (6), 839-845.
4. Brotz, H.; Bierbaum, G.; Leopold, K.; Reynolds, P.E.; Sahl, H.G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 1998, 42 (1), 154-160.
5. Brotz, H.; Bierbaum, G.; Reynolds, P.E.; Sahl, H.G. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur. J. Biochem. 1997, 246 (1), 193-199.
6. Chatterjee, C.; Paul, M.; Xie, L.; Van der Donk, W.A. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 2005, 105 (2), 633-683.
7. Altena, K.; Guder, A.; Cramer, C.; Bierbaum, G. Biosynthesis of the lantibiotic mersacidin: Organisation of a type B lantibiotic gene cluster. Appl. Environ. Microbiol. 2000, 66 (6), 2565-2571.
8. Boakes, S.; Cortes, J.; Appleyard, A.N.; Rudd, B.A.M.; Dawson, M.J. Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system. Mol. Microbiol. 2009, 72 (5), 1126-1136.
9. Boakes, S.; Appleyard, A.N.; Cortes, J.; Dawson, M.J. Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362. J. Antibiot. 2010, 63 (7), 351-358.
10. Appleyard, A.N.; Choi, S.; Read, D.M.; Lightfoot, A.; Boakes, S.; Hoffmann, A.; Chopra, I.; Bierbaum, G.; Rudd, B.A.M.; Dawson, M.J.; Cortes, J. Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem. Biol. 2009, 16 (5), 490-498.
11. Boakes, S.; Ayala, T.; Herman, M.; Appleyard, A.N.; Dawson, M.J.; Cortes, J. Generation of an actagardine A variant library through saturation mutagenesis. Appl. Microbiol. Biotechnol. 2012, 95 (6), 1509-1517.
12. Majer, F.; Schmid, D.G.; Altena, K.; Bierbaum, G.; Kupke, T. The flavoprotein MrsD catalyses the oxidative decarboxylation reaction involved in formation of the peptidoglycan biosynthesis inhibitor mersacidin. J. Bacteriol. 2002, 184 (5), 1234-1243.
13. Szekat, C.; Jack, R.W.; Skutlarek, D.; Färber, H.; Bierbaum, G. Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl. Environ. Microbiol. 2003, 69 (7), 3777-3783.
14. Bartlett, J.G.; Chang, T.W.; Gurwith, M.; Gorbach, S. L.; Onderdonk, A.B. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 1978, 298 (10), 531-534.
15. Warny, M.; Pepin, J.; Fang, A.; Killgore, G.; Thompson, A.; Brazier, J.; Frost, E.; McDonald, L.C. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366 (9491), 1079-1084.
16. Stabler, R.A.; He, M.; Dawson, L.; Martin, M.; Corton, C.; Lawley, D.; Sebaihia, M.; Quail, M.A.; Rose, G.; Gerding, D.N.; Gibert, M.; Popoff, M.R.; Parkhill, J.; Dougan, G.; Wren, B.W. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 2009, 10(9), R102.
17. Pelaez, T.; Cercenado, E.; Alcala, L.; Marin, M.; Martin-Lopez, A.; Martinez-Alarcon, J.; Catalan, P.; Sanchez-Somolinos, M.; Bouza, E. Metronidazole resistance in Clostridium difficile is heterogenous. J. Clin. Microbiol. 2008, 46 (9), 3028-3032.
18. Floch, M.H.; Walker, W.A.; Madsen, K.; Sanders, M.E.; Macfarlane, G.T.; Flint, H.J.; Dieleman, L.A.; Ringel, Y.; Guandalini, S.; Kelly, C.P.; Brandt L.J. Recommendations for probiotic use-2011 update. J. Clin. Gastroenterol. 2011, 45 Suppl, S168-S171.
19. Louie, T.J.; Cannon, K.; Byrne, B.; Emery, J.; Ward, L.; Eyben, M.; Krulicki, W. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI. Clin. Infect. Dis. 2012, 55 (Suppl. 2), S132-S142.
20. Crowther, G.S.; Baines, S.D.; Todhunter, S.L.; Freeman, J.; Chilton, C.H.; Wilcox, M.H. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 2013, 68 (1), 168-176.
21. Reunanen, J.; Saris, P.E.J. Survival of nisin activity in intestinal environment. Biotechnol. Lett. 2009, 31 (8), 1229-1232.
22. Febbraro, S.; Hancock, A.; Boyd, A.; Dawson, M.J. A Phase I, Double-Blind, Randomised, Placebo-Controlled, Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of NVB302 Administered Orally to Healthy Volunteers. Poster F-1540C presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2012, San Francisco.